Bhaskar Dasgupta, ACR 2022: Unmet needs in the treatment of polymyalgia rheumatica
Polymyalgia rheumatica (PMR) is an inflammatory condition presenting as pain and stiffness in shoulder, neck and hip muscles, the underlying cause is unknown; however, recent studies have linked PMR to elevated IL-6 levels. In this interview with Prof. Bhaskar Dasgupta (Southend University Hospital NHS Foundation Trust, Southend-on-Sea, UK) we discuss the pathophysiology of PMR and the unmet needs in its treatment.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)‘ (Abstract number: 1676) was presented at the ACR Convergence, November 10–14, 2022.
- Could you tell us a little about relapsing polymyalgia rheumatica (PMR) and the unmet needs in its treatment? (1:51)
Disclosures: Bhaskar Dasgupta discloses consulting for Sanofi; receiving grant/ research support from Sanofi; and receiving honoraria from Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Vasculitis
Naomi J Patel, ACR 2022: Impact of tocilizumab on HbA1C during giant cell arteritis treatment
GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, USA) to discuss the aims, design and findings from her post-hoc analysis of the GiACTA […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Lisa Christ, ACR 2022: Tocilizumab and ultra-short glucocorticoids in giant cell arteritis – one year follow-up of GUSTO
The GUSTO trial (NCT03745586) investigated the efficacy and safety of tocilizumab (TCZ )-monotherapy after ultra-short glucocorticoid treatment in new-onset giant cell arteritis (GCA). touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss this analysis of GUSTO exploring the maintenance of remission 1 year after discontinuation of TCZ treatment. This […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!